NBIX heads into the week with an interesting split: Goldman Sachs reinstated coverage with a Buy and a $213 target on the same day the stock fell nearly 4%.
The analyst activity has been firmly bullish. Goldman's reinstatement on June 2 — setting a target 38% above the closing price of $154.84 — arrived alongside a broader pattern of Street upgrades. Bernstein initiated at Outperform with a $221 target in late May. RBC raised its target twice in four weeks, most recently to $183. JP Morgan lifted to $185 after Q1 results. The consensus now sits at Buy with a mean target of $192.88, implying roughly 24% upside from current levels. The outlier is Morgan Stanley, holding Equal-Weight with a $191 target — a position that stands apart from the near-unanimous bullish lean elsewhere.
The bull case rests on Ingrezza and Crenessity franchise momentum, confirmed by a strong Q1 print and a raised financial guidance. The bear case is more structural: pricing pressure, increasing competition, and the eventual loss of Ingrezza exclusivity in the late 2030s. For now, the bulls have the louder voice. EPS momentum ranks in the 89th percentile on a 90-day basis and the 82nd percentile over 30 days. EPS surprise percentile is 71. The ORTEX stock score has held near 86 for most of May, with momentum the rising component — climbing from around 69 to 78 since early May as the post-earnings rally was digested.
Short interest is not the story here, but it has shifted in a way worth noting. At 5.2% of the free float, it sits at a moderate level — and it dropped sharply over the past week, falling roughly 11% from around 5.9 million shares to just over 5.2 million. That pullback follows a period of elevated positioning through mid-May, when short interest briefly pushed toward 6 million shares. The lending market confirms the low tension: availability is extremely loose at 4,682% of short interest, meaning there are roughly 98 million shares available to borrow against an estimated 5.2 million shorted. Cost to borrow is minimal at 0.45% — a level that signals no meaningful demand pressure from short sellers.
Options are modestly more defensive than usual. The put/call ratio has edged up to 0.98, about 1.3 standard deviations above its 20-day average of 0.93. That's not an alarming level — the 52-week high is 1.76 — but it does mark a visible drift toward hedging over the past two weeks. The PCR was as low as 0.87 in mid-May, so the shift is real, even if the overall positioning stays far from extreme. Peers are weaker on the week: TGTX fell 7.8% and NUVL dropped nearly 13%, while IONS lost 4%. NBIX's 0.6% weekly decline looks measured in that context.
Insider selling has been active. The Chief Scientific Officer sold 22,000 shares across two transactions — on May 27 and June 1 — at prices between $155.53 and $160.25, for combined proceeds of roughly $3.5 million. A second C-suite executive sold 2,261 shares in late May. These are routine-sized transactions with low significance scores, and they arrive in a stock that has gained 17% over the past month following its Q1 beat. The 90-day net insider position is actually positive at roughly 292,000 net shares — driven by director award grants — so the recent sales don't shift the broader picture.
The next scheduled catalyst is Q2 earnings on July 31. After Q1, NBIX jumped nearly 10% on the day and 16% over the following week — the clearest data point in the history available. What to watch between now and then: whether the Goldman reinstatement draws additional institutional interest at current levels, and whether the put/call ratio drifts further toward its recent highs as the earnings date approaches.
See the live data behind this article on ORTEX.
Open NBIX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
